WO2002081630A3 - Use of semenogelin in the diagnosis, prognosis and treatment of cancer - Google Patents

Use of semenogelin in the diagnosis, prognosis and treatment of cancer Download PDF

Info

Publication number
WO2002081630A3
WO2002081630A3 PCT/US2002/010535 US0210535W WO02081630A3 WO 2002081630 A3 WO2002081630 A3 WO 2002081630A3 US 0210535 W US0210535 W US 0210535W WO 02081630 A3 WO02081630 A3 WO 02081630A3
Authority
WO
WIPO (PCT)
Prior art keywords
cancer
semenogelin
mammal
test sample
immune
Prior art date
Application number
PCT/US2002/010535
Other languages
French (fr)
Other versions
WO2002081630A2 (en
Inventor
David D Roberts
Henry C Krutzsch
Original Assignee
Us Gov Sec Health
David D Roberts
Henry C Krutzsch
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Us Gov Sec Health, David D Roberts, Henry C Krutzsch filed Critical Us Gov Sec Health
Priority to AU2002254524A priority Critical patent/AU2002254524A1/en
Priority to US10/474,213 priority patent/US7618789B2/en
Publication of WO2002081630A2 publication Critical patent/WO2002081630A2/en
Publication of WO2002081630A3 publication Critical patent/WO2002081630A3/en
Priority to US12/609,817 priority patent/US20100112626A1/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57423—Specifically defined cancers of lung
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/5743—Specifically defined cancers of skin, e.g. melanoma
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57488—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds identifable in body fluids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups

Abstract

A method of diagnosing cancer in a male mammal, wherein the cancer is other than prostate cancer, which method comprises obtaining a test sample from the male mammal and subsequently assaying the test sample for an increased level of semenogelin, wherein the increased level of semenogelin in the test sample is diagnostic for the cancer; a method of diagnosing cancer in a female mammal, which method comprises obtaining a test sample from the female mammal and subsequently assaying the test sample for the presence of semenogelin, wherein the presence of semenogelin in the test sample is diagnostic for the cancer; a method of prognosticating a cancer in a mammal, wherein the cancer is other than prostate cancer and semenogelin is a marker for the cancer, which method comprises measuring the level of semenogelin in a test sample obtained from the mammal, wherein the level of semenogelin in the test sample is indicative of the prognosis of the cancer in the mammal; a method of assessing the effectiveness of treatment of a cancer in a mammal, wherein the cancer is other than prostate cancer and semenogelin is a marker for the cancer, which method comprises measuring the level of semenogelin in a test sample obtained from the mammal, wherein the level of semenogelin in the test sample is indicative of the effectiveness of the treatment of the cancer in the mammal; a method of inducing an immune response to a cancer in a mammal, wherein the cancer is other than prostate cancer and semenogelin is a marker for the cancer, which method comprises administering to the mammal a composition comprising (a) an immune-response inducing effective amount of (i) a semenogelin protein or polypeptide fragment thereof or (ii) and antibody or antigenically reactive fragment thereof that is specific for a semenogelin protein or polypeptide fragment thereof or (b) a recombinant vector encoding and expressing an immune-response inducing effective amount of (i) or (ii), whereupon an immune response to the cancer is induced; and a composition comprising a pharmaceutically acceptable carrier and (a) an immune-response inducing effective amount of (i) a polypeptide of any of SEQ ID NOS:1-27 or (ii) an antibody or antigenically reactive fragment thereof that is specific for a polypeptide of any of SEQ ID NOS:1-27 or (b) a recombinant vector encoding and expressing an immune-response inducing effective amount of (i) or (ii).
PCT/US2002/010535 2001-04-06 2002-04-03 Use of semenogelin in the diagnosis, prognosis and treatment of cancer WO2002081630A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
AU2002254524A AU2002254524A1 (en) 2001-04-06 2002-04-03 Use of semenogelin in the diagnosis, prognosis and treatment of cancer
US10/474,213 US7618789B2 (en) 2001-04-06 2002-04-03 Use of semenogelin in the diagnosis, prognosis and treatment of cancer
US12/609,817 US20100112626A1 (en) 2001-04-06 2009-10-30 Use of Semenogelin in the Diagnosis, Prognosis and Treatment of Cancer

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US28199401P 2001-04-06 2001-04-06
US60/281,994 2001-04-06

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US12/609,817 Division US20100112626A1 (en) 2001-04-06 2009-10-30 Use of Semenogelin in the Diagnosis, Prognosis and Treatment of Cancer

Publications (2)

Publication Number Publication Date
WO2002081630A2 WO2002081630A2 (en) 2002-10-17
WO2002081630A3 true WO2002081630A3 (en) 2003-11-13

Family

ID=23079642

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2002/010535 WO2002081630A2 (en) 2001-04-06 2002-04-03 Use of semenogelin in the diagnosis, prognosis and treatment of cancer

Country Status (3)

Country Link
US (2) US7618789B2 (en)
AU (1) AU2002254524A1 (en)
WO (1) WO2002081630A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8664183B2 (en) * 2009-02-27 2014-03-04 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services SPANX-B polypeptides and their use
CA3161701A1 (en) * 2020-01-21 2021-07-29 Zhaoli LI Semg2 antibody and use thereof
EP4310098A1 (en) * 2021-03-16 2024-01-24 Shanghai Biotroy Biotechnique Co., Ltd. Semenogelin neutralizing antibody and epitope and application thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5972615A (en) * 1998-01-21 1999-10-26 Urocor, Inc. Biomarkers and targets for diagnosis, prognosis and management of prostate disease

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7748A (en) * 1850-10-29 Improvement in machines for nicking the heads of wood-screws
NL154598B (en) 1970-11-10 1977-09-15 Organon Nv PROCEDURE FOR DETERMINING AND DETERMINING LOW MOLECULAR COMPOUNDS AND PROTEINS THAT CAN SPECIFICALLY BIND THESE COMPOUNDS AND TEST PACKAGING.
US3817837A (en) 1971-05-14 1974-06-18 Syva Corp Enzyme amplification assay
US3939350A (en) 1974-04-29 1976-02-17 Board Of Trustees Of The Leland Stanford Junior University Fluorescent immunoassay employing total reflection for activation
US3996345A (en) 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4275149A (en) 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
US4277437A (en) 1978-04-05 1981-07-07 Syva Company Kit for carrying out chemically induced fluorescence immunoassay
US4366241A (en) 1980-08-07 1982-12-28 Syva Company Concentrating zone method in heterogeneous immunoassays
US4569788A (en) 1983-05-18 1986-02-11 The United States Of America As Represented By The Department Of Health And Human Services Monoclonal antibodies against non small cell lung cancer
US6040138A (en) 1995-09-15 2000-03-21 Affymetrix, Inc. Expression monitoring by hybridization to high density oligonucleotide arrays
US5800992A (en) 1989-06-07 1998-09-01 Fodor; Stephen P.A. Method of detecting nucleic acids
US5279721A (en) 1993-04-22 1994-01-18 Peter Schmid Apparatus and method for an automated electrophoresis system
US5866679A (en) 1994-06-28 1999-02-02 Merck & Co., Inc. Peptides
US6143864A (en) 1994-06-28 2000-11-07 Merck & Co., Inc. Peptides
US5599686A (en) 1994-06-28 1997-02-04 Merck & Co., Inc. Peptides
US6177404B1 (en) 1996-10-15 2001-01-23 Merck & Co., Inc. Conjugates useful in the treatment of benign prostatic hyperplasia
US6504014B1 (en) 1997-05-19 2003-01-07 The John Hopkins University Tissue specific prodrug
AU7582298A (en) 1997-05-19 1998-12-11 Johns Hopkins University School Of Medicine, The Tissue specific prodrug
JP2001516009A (en) 1997-07-17 2001-09-25 ルードヴィッヒ インスティテュート フォー キャンサー リサーチ Cancer-related nucleic acids and polypeptides
WO1999061471A2 (en) 1998-05-29 1999-12-02 Incyte Pharmaceuticals, Inc. Human transmembrane proteins
US6335170B1 (en) 1999-02-22 2002-01-01 Torben F. Orntoft Gene expression in bladder tumors

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5972615A (en) * 1998-01-21 1999-10-26 Urocor, Inc. Biomarkers and targets for diagnosis, prognosis and management of prostate disease

Also Published As

Publication number Publication date
US20100112626A1 (en) 2010-05-06
WO2002081630A2 (en) 2002-10-17
US20040214248A1 (en) 2004-10-28
US7618789B2 (en) 2009-11-17
AU2002254524A1 (en) 2002-10-21

Similar Documents

Publication Publication Date Title
Palma et al. Detection of collagen triple helix repeat containing-1 and nuclear factor (erythroid-derived 2)-like 3 in colorectal cancer
CA2633171A1 (en) Antibodies against tumor-associated antigenic target (tat) polypeptides
CA2386858A1 (en) 36p6d5: secreted tumor antigen
JP3507079B2 (en) Early detection of prostate cancer (CAP) by measuring ratios including prostate specific antigen (PSA) and human gland kallikrein (HGK-1) concentrations
CA2249742A1 (en) Compounds and methods for immunotherapy and immunodiagnosis of prostate cancer
BR9917218A (en) Monoclonal antibodies, antigens, and diagnosis and therapy of malignancies
WO2003089616A3 (en) Soluble mic polypeptides as markers for diagnosis, prognosis and treatment of cancer and autoimmune diseases or conditions
WO2000056352A3 (en) Reagents and methods useful for detecting diseases of the prostate
WO2012031374A1 (en) Blood markers for diagnosing epithelium derived cancers and monoclonal antibodies thereof
JP2002542157A5 (en)
JP2010528261A5 (en)
WO1998010069A3 (en) E25a protein, methods for production and use thereof
James et al. Salivary duct carcinoma secreting prostate-specific antigen
Javadpour Multiple biochemical tumor markers in seminoma. A double‐blind study
WO2002008260A3 (en) Bstp-ecg1 protein and related reagents and methods of use thereof
US20160195538A1 (en) Compositions and methods for detecting, diagnosing, and treating cancer
WO2002081630A3 (en) Use of semenogelin in the diagnosis, prognosis and treatment of cancer
JP2001517445A5 (en)
CA2472163A1 (en) Psoriasin expression by breast epithelial cells
US6489128B1 (en) Methods for detecting cancer of the central nervous system
AU746635B2 (en) Method of detecting prostate specific antigen
ES2267291T3 (en) METHOD OF DIAGNOSIS, CONTROL, DETERMINATION OF THE STADIUM, OBTAINING IMAGES AND TREATMENT OF GYNECOLOGICAL CANCERS.
WO2001065262A3 (en) Reagents and methods useful for detecting diseases of the breast
AU4098201A (en) Method for diagnosing efficacy of xenotypic antibody therapy
JP2008249587A (en) Tumor determination method with calmodulin used as target

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWE Wipo information: entry into national phase

Ref document number: 10474213

Country of ref document: US

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP